Cantor Fitzgerald upgraded Madrigal Pharmaceuticals (MDGL) to Overweight from Neutral.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $533 from $431 at Clear Street
- Madrigal Pharmaceuticals reports Q3 EPS ($5.08) vs ($4.92) last year
- Madrigal Pharmaceuticals management to meet with Citizens
- Madrigal Pharmaceuticals upgraded to Neutral at BofA after Rezdiffra outperforms
- Madrigal Pharmaceuticals upgraded to Neutral from Underperform at BofA